Jun 8 2012
DiaGenic ASA [OSL:DIAG] (OSE:DIAG) today announced that the first
patient with MCI (Mild Cognitive Impairment) was examined with [18F]
Flutemetamol PET imaging at University of Lund Sweden in the DiaGenic
and GE Healthcare Research Collaboration announced March 27th 2012.
First patient examined with PET imaging means that the clinical phase of
the collaboration has been initiated.
The study aims to develop a blood-based gene expression profile in
patients with mild cognitive impairment (MCI) to be used in conjunction
with PET imaging of the brain. The PET imaging agent, [18F]
Flutemetamol, is currently in phase 3 development and is not yet
approved by any regulatory authority.
The aim of the project is to recruit 180 individuals with amnestic MCI,
together with 30 patients with clinically diagnosed mild to moderate AD.
AI-powered ECG model predicts heart disease risk with precision